Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer

Phase 3 Completed 361 enrolled European Lung Cancer Working Party

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival in comparison to a regimen containing etoposide and without platinum derivative.

Timeline

Start: 2000-04
Primary completion: 2013-12
Completion: 2015-02

Publications

Berghmans T, Scherpereel A, Meert AP, Giner V, Lecomte J, Lafitte JJ, Leclercq N, Paesmans M, Sculier JP; European Lung Cancer Working Party (ELCWP). A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer. Front Oncol. 2017 Sep 19;7:217. doi: 10.3389/fonc.2017.00217. eCollection 2017.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Cisplatin	Other / unclassified	90 mg/m2	Intravenous
Subject	Epirubicin	Small molecule	60 mg/m2	Intravenous
Subject	Ifosfamide	Small molecule	1.5 g	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	—	—
Comparator	Etoposide	Small molecule	100 mg/m2	Intravenous

Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications